Sana Biotechnology Current Ratio vs. Current Valuation
| SANA Stock | USD 2.61 0.26 11.06% |
Current Ratio | First Reported 2010-12-31 | Previous Quarter 3.31097746 | Current Value 3.15 | Quarterly Volatility 6.58693646 |
For Sana Biotechnology profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Sana Biotechnology to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Sana Biotechnology utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Sana Biotechnology's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Sana Biotechnology over time as well as its relative position and ranking within its peers.
Sana |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sana Biotechnology. If investors know Sana will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sana Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.40) | Return On Assets (0.31) | Return On Equity (0.93) |
The market value of Sana Biotechnology is measured differently than its book value, which is the value of Sana that is recorded on the company's balance sheet. Investors also form their own opinion of Sana Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is Sana Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sana Biotechnology's market value can be influenced by many factors that don't directly affect Sana Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sana Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sana Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sana Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Sana Biotechnology Current Valuation vs. Current Ratio Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Sana Biotechnology's current stock value. Our valuation model uses many indicators to compare Sana Biotechnology value to that of its competitors to determine the firm's financial worth. Sana Biotechnology is rated below average in current ratio category among its peers. It is rated below average in current valuation category among its peers reporting about 94,264,990 of Current Valuation per Current Ratio. At present, Sana Biotechnology's Current Ratio is projected to decrease significantly based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Sana Biotechnology's earnings, one of the primary drivers of an investment's value.Sana Current Valuation vs. Current Ratio
Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Sana Biotechnology |
| = | 5.09 X |
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Sana Biotechnology |
| = | 479.81 M |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Sana Current Valuation vs Competition
Sana Biotechnology is rated below average in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is at this time estimated at about 25.2 Billion. Sana Biotechnology claims roughly 479.81 Million in current valuation contributing just under 2% to equities under Health Care industry.
Sana Biotechnology Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Sana Biotechnology, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Sana Biotechnology will eventually generate negative long term returns. The profitability progress is the general direction of Sana Biotechnology's change in net profit over the period of time. It can combine multiple indicators of Sana Biotechnology, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -60 K | -63 K | |
| Operating Income | -326.9 M | -343.2 M | |
| Income Before Tax | -283.3 M | -297.4 M | |
| Total Other Income Expense Net | 43.6 M | 45.8 M | |
| Net Loss | -242.5 M | -254.7 M | |
| Net Loss | -283.3 M | -297.4 M | |
| Net Interest Income | 9.9 M | 10.4 M | |
| Interest Income | 9.9 M | 10.4 M | |
| Net Loss | -283.3 M | -297.4 M | |
| Income Tax Expense | -3.6 M | -3.7 M | |
| Non Operating Income Net Other | -606.6 K | -576.3 K | |
| Change To Netincome | 29.5 M | 53.9 M | |
| Net Loss | (1.46) | (1.53) | |
| Income Quality | 0.90 | 0.65 | |
| Net Income Per E B T | 0.89 | 0.78 |
Sana Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Sana Biotechnology. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Sana Biotechnology position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Sana Biotechnology's important profitability drivers and their relationship over time.
Use Sana Biotechnology in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Sana Biotechnology position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Sana Biotechnology will appreciate offsetting losses from the drop in the long position's value.Sana Biotechnology Pair Trading
Sana Biotechnology Pair Trading Analysis
The ability to find closely correlated positions to Sana Biotechnology could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Sana Biotechnology when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Sana Biotechnology - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Sana Biotechnology to buy it.
The correlation of Sana Biotechnology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Sana Biotechnology moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Sana Biotechnology moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Sana Biotechnology can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Sana Biotechnology position
In addition to having Sana Biotechnology in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run World Allocation Funds Thematic Idea Now
World Allocation Funds
Funds or Etfs investing in stocks, bonds, and cash of domestic markets as well as in markets of Canada, Japan, and Europe. The World Allocation Funds theme has 37 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize World Allocation Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Check out World Market Map. For information on how to trade Sana Stock refer to our How to Trade Sana Stock guide.You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
To fully project Sana Biotechnology's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Sana Biotechnology at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Sana Biotechnology's income statement, its balance sheet, and the statement of cash flows.